This cross-sectional analysis of 4,366 NHANES participants (2017–2023), representing 154.5 million US adults aged 30–79 without known ASCVD, compared statin eligibility for primary prevention under the 2026 AHA/ACC dyslipidemia guideline versus the 2018 guideline.
The 2026 guideline makes an estimated 87.5 million adults (56.6%) statin eligible, adding 21.5 million newly eligible individuals (13.9%) — mostly younger, lower-risk adults with a mean 10-year ASCVD risk of 3.1% vs. 6.1% for those previously eligible. Eligibility exceeds 93% in adults aged 70–79 and 85% in those aged 60–69, but is only 11% in those aged 30–39.
Cross-sectional design limits causal inference; full guideline text was not accessible (only abstract/results available), so nuances of new risk-estimation methodology cannot be fully assessed; NHANES self-report of statin use may introduce misclassification.
The 2026 guideline substantially broadens who gets offered a statin, especially older adults and younger, lower-risk patients — clinicians should be prepared for shared decision-making conversations with many patients who were not previously candidates. The low mean 10-year ASCVD risk (3.1%) in newly eligible patients means absolute benefit will be modest; individualized risk-benefit discussions remain essential.
Explore related topics
